Does ARNI improve cardiac reverse remodeling compared to ACEi/ARB in patients with HFrEF?
ARNI therapy improves cardiac reverse remodeling (LV size and hypertrophy) more effectively than ACEi/ARB in patients with HFrEF, with benefits seen as early as 3 months.
. Conclusions ARNI distinctly improved left ventricular size and hypertrophy compared with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers in HF with reduced EF patients, even after short-term follow-up. Patients appeared to benefit more in terms of CRR treated with ARNI as early as possible and for at least 3 months. Further large sample trials are required to determine the effects of ARNI on CRR in HF with preserved EF patients.
Wang et al. (Wed,) studied this question.